Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fast-track pneumonia pathway focusing on early progressive mobilisation: a clinical feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sharing and reuse of individual participant data from clinical trials: principles and recommendations

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early vasopressor use following traumatic injury: a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Platelet increment is not associated with endothelial damage in haematological patients: a prospective observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Only minor stem cell mobilization in head and neck irradiated patients treated with hyperbaric oxygen

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Not enough is known regarding the prognosis and treatment of necrotising soft tissue infections (NSTIs). Mortality has been shown to be 25%-35%, with survivors coping with amputations and prolonged rehabilitation. This study will evaluate soluble urokinase-type plasminogen activator receptor (suPAR) as a possible prognostic marker of NSTI severity and mortality, as well as whether hyperbaric oxygen therapy (HBOT) can modulate markers of endothelial damage during NSTI. We hypothesise that in patients with NSTI, suPAR can provide prognostic risk assessment on hospital admission and that HBOT can reduce the endothelial damage that these patients are exposed to.

METHODS AND ANALYSIS: This is a prospective observational study. Biomarkers will be measured in 150 patients who have been diagnosed with NSTI. On admission, baseline blood samples will be obtained. Following surgery and HBOT, daily blood samples will be obtained in order to measure endothelial and prognostic biomarkers (soluble thrombomodulin, syndecan-1, sE-selectin, vascular endothelial (VE)-cadherin, protein C and suPAR levels). Clinical data will be acquired during the first 7 days of stay in the intensive care unit. The primary outcomes in studies I and II will be endothelial biomarker levels after HBOT, and in study III suPAR levels as a marker of disease prognosis and severity.

ETHICS AND DISSEMINATION: The study has been approved by the Regional Scientific Ethical Committee of Copenhagen (H-16021845) and the Danish Data Protection Agency (RH-2016-199). Results will be presented at national and international conferences and published in peer-reviewed scientific journals.

TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier NCT03147352. (Pre-results).

Original languageEnglish
JournalB M J Open
Volume7
Issue number10
Pages (from-to)e017805
ISSN2044-6055
DOIs
Publication statusPublished - 5 Oct 2017

    Research areas

  • Journal Article

ID: 51804658